SHAANXI CHAONAN FUTURE TRADING CO., LTD – Trademark Portfolio

Entity Type: 99

SHAANXI CHAONAN FUTURE TRADING CO., LTD holds 1 U.S. trademark filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 1 filings in this category. Currently, 1 trademark is registered. Notable registered marks include YOUCEFORCE. The owner is based in XI'AN CITY, SHAANXI PROVINCE.

ROOM 0401, UNIT 1, BUILDING 15, NO. 17, ERFUZHUANG RESIDENTIAL AREA, WEIYANG DISTRICT

XI'AN CITY, SHAANXI PROVINCE 710000 , CN

1 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

Trademark Classifications

SHAANXI CHAONAN FUTURE TRADING CO., LTD's trademark portfolio spans 1 Nice Classification class, reflecting the scope of goods and services protected under their brand portfolio.

5
Pharmaceuticals (1 filing)

Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes

Frequently Asked Questions

How many trademarks does SHAANXI CHAONAN FUTURE TRADING CO., LTD have?

SHAANXI CHAONAN FUTURE TRADING CO., LTD has 1 U.S. trademark filed with the USPTO. Of these, 1 registered.

What trademark classes does SHAANXI CHAONAN FUTURE TRADING CO., LTD file in?

SHAANXI CHAONAN FUTURE TRADING CO., LTD files trademarks across 1 Nice Classification class. The most active classes are Class 5 (Pharmaceuticals). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.

What are SHAANXI CHAONAN FUTURE TRADING CO., LTD's most well-known trademarks?

SHAANXI CHAONAN FUTURE TRADING CO., LTD's registered trademark portfolio includes well-known marks such as YOUCEFORCE. These are among 1 currently registered trademark in the portfolio.

What is SHAANXI CHAONAN FUTURE TRADING CO., LTD's trademark registration success rate?

SHAANXI CHAONAN FUTURE TRADING CO., LTD has a 100% trademark registration rate, with 1 out of 1 resolved applications resulting in successful registration. Currently, 0 applications are pending review.